SYNE1 and cancer: CPG2 is sometimes used in the clinic to reduce excess concentration of methotrexate in cancer patients by converting it into 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate, which are both non-toxic and metabolised by the liver [14], and so is known to be safe in the clinic.